Sarah Bevington, PhD

Dr. Sarah Bevington is a QC scientist at Labcorp Biopharmaceutical CMC Services in the molecular biology and virology department. In this role, Sarah is responsible for a wide range of GLP and GCP studies at all stages of development using molecular biology techniques such as qPCR and ddPCR. She works closely with clients to deliver assays that are fit for purpose and are compliant with regulatory guidelines.

Read more about Sarah Bevington, PhD»
April 6, 2023

Labcorp declares quarterly dividend

BURLINGTON, N.C. , April 6, 2023 /PRNewswire/ -- Labcorp  (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 8, 2023 , to stockholders of record as of
Read more »
<span>Labcorp announces 2022 Corporate Responsibility Report</span>
March 31, 2023

Labcorp announces 2022 Corporate Responsibility Report

Every day, millions of people count on Labcorp to help them better understand their healthcare needs, and we take that responsibility very seriously. As a leading global life sciences company, we recognize that we also have a tremendous responsibility to demonstrate progress on important environmental, social and governance (ESG) efforts, and to make a positive impact for the patients, providers, consumers and business leaders who rely on us.
Read more »
March 31, 2023

Labcorp to announce first quarter financial results on April 25, 2023

BURLINGTON, N.C., March 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2023 before the market opens on Tuesday, April 25, 2023 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
Read more »